• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    Protalix BioTherapeutics, Inc. (PLX)

    0.84 Up 0.04(5.00%) Feb 5, 4:00PM EST
    ProfileGet Profile for:
    Protalix BioTherapeutics, Inc.
    2 Snunit Street
    Science Park
    Carmiel, 21000
    Israel - Map
    Phone: 972 4 988 9488
    Fax: 972 4 988 9489
    Website: http://www.protalix.com

    Index Membership:N/A
    Full Time Employees:234

    Business Summary 

    Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-106, an oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and PRX-112, an orally administered glucocerebrosidase enzyme (GCD) for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD produced and encapsulated within carrot cells. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Protalix BioTherapeutics, Inc.

    Key Executives 
    Mr. Moshe Manor , 60
    Chief Exec. Officer, Pres and Director
    Dr. Yoseph Shaaltiel Ph.D., 62
    Founder and Exec. VP of R&D
    Mr. Yossi Maimon CPA, MBA, 45
    Chief Financial Officer, VP, Sec. and Treasurer
    Mr. Tzvi Palash M.Sc., B.Sc., 59
    Chief Operating Officer
    Dr. Einat Brill Almon Ph.D., 56
    Sr. VP of Product Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders